Abrocitinib: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Abrocitinib. Educational only — not medical advice.
Labeled uses
CIBINQO is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable. Limitations of Use CIBINQO is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or other immunosuppressants.
Source: FDA labeling via NIH DailyMed (set 16c12a56…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.